Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation (CCRT) for Cervical Cancer on Overall Survival
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the effect of waiting time, from diagnosis to initiation of definitive concurrent chemoradiation (CCRT), on overall survival in cervical cancer patients. Materials and methods: Patients with cervical cancer who were treated with definitive CCRT between 2000 and 2017 were retrospectively reviewed. Time from initial pathological diagnosis to definitive CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in two groups (group 1 ≤ median, group 2 > median). Patients with a waiting time of more than 60 days were excluded. Results: The median waiting time was 14 days (0-60). There were differences between group 1 and group 2 in age and chemotherapy regimens. However, no significant difference was found in the International Federation of Gynecology and Obstetrics stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (group 1 vs. group 2, p=0.042). On multivariate analysis, intervals as either a continuous variable (hazard ratio [HR], 1.023; 95% confidence interval [CI], 1.006 to 1.040; p=0.007) or a categorical variable (HR, 1.513; 95% CI, 1.073 to 2.134; p=0.018), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival. Conclusion: A shorter waiting time from pathological diagnosis to definitive CCRT showed benefit on overall survival. Our findings suggest that an effort to minimize waiting times should be recommended in cervical cancer patients who are candidates for CCRT.
Abstract
Purpose: This study aimed to evaluate the effect of waiting time, from diagnosis to initiation of definitive concurrent chemoradiation (CCRT), on overall survival in cervical cancer patients. Materials and methods: Patients with cervical cancer who were treated with definitive CCRT between 2000 and 2017 were retrospectively reviewed. Time from initial pathological diagnosis to definitive CCRT was analyzed both as a continuous variable (per day) and as a categorical variable in two groups (group 1 ≤ median, group 2 > median). Patients with a waiting time of more than 60 days were excluded. Results: The median waiting time was 14 days (0-60). There were differences between group 1 and group 2 in age and chemotherapy regimens. However, no significant difference was found in the International Federation of Gynecology and Obstetrics stage, cell type, or the number of cycles of chemotherapy received during CCRT. A longer waiting time was associated with poorer overall survival on the Kaplan-Meier curve (group 1 vs. group 2, p=0.042). On multivariate analysis, intervals as either a continuous variable (hazard ratio [HR], 1.023; 95% confidence interval [CI], 1.006 to 1.040; p=0.007) or a categorical variable (HR, 1.513; 95% CI, 1.073 to 2.134; p=0.018), FIGO stage, cell type, and the number of cycles of chemotherapy received during CCRT were significant independent prognostic factors for overall survival. Conclusion: A shorter waiting time from pathological diagnosis to definitive CCRT showed benefit on overall survival. Our findings suggest that an effort to minimize waiting times should be recommended in cervical cancer patients who are candidates for CCRT.
참고문헌 (29)
- Arbyn M, "Estimates of incidence and mortality of cervical cancer in 2018 : a worldwide analysis", Lancet Glob Health, 8, pp.e191~e203 (2020)
- Keys HM, "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma", N Engl J Med, 340, pp.1154~1161 (1999)
- Peters WA 3rd, "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix", J Clin Oncol, 18, pp.1606~1613 (2000)
- Whitney CW, "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes : a Gynecologic Oncology Group and Southwest Oncology Group study", J Clin Oncol, 17, pp.1339~1348 (1999)
- Morris M, "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer", N Engl J Med, 340, pp.1137~1143 (1999)
- Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer", N Engl J Med, 340, pp.1144~1153 (1999)
- Wyatt RM, "Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules", Br J Radiol, 81, pp.549~563 (2008)
- Mackillop WJ, "A comparison of delays in the treatment of cancer with radiation in Canada and the United States", Int J Radiat Oncol Biol Phys, 32, pp.531~539 (1995)
- Ferreira da Silva I, "Cervical cancer treatment delays and associated factors in a cohort of women from a developing country", J Glob Oncol, 5, pp.1~11 (2019)
- Umezu T, "Prognostic factors in stage IA-IIA cervical cancer patients treated surgically : does the waiting time to the operation affect survival?", Arch Gynecol Obstet, 285, pp.493~497 (2012)
- Choan E, "Radical radiotherapy for cervix cancer : the effect of waiting time on outcome", Int J Radiat Oncol Biol Phys, 61, pp.1071~1077 (2005)
- Benard VB, "Timeliness of cervical cancer diagnosis and initiation of treatment in the National Breast and Cervical Cancer Early Detection Program", J Womens Health(Larchmt), 21, pp.776~782 (2012)
- Choi CH, "The anti-cancer effects of itraconazole in epithelial ovarian cancer", Sci Rep, 7, pp.6552~ (2017)
- Croke J, "Radiation therapy quality-of-care indicators for locally advanced cervical cancer : a consensus guideline", Pract Radiat Oncol, 6, pp.315~323 (2016)
- Cionini L, "Quality indicators in radiotherapy", Radiother Oncol, 82, pp.191~200 (2007)
- Nascimento MI, "Waiting time for radiotherapy in women with cervical cancer", Rev Saude Publica, 49, pp.92~ (2015)
- Lee YY, "Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis", Anticancer Res, 33, pp.4675~4681 (2013)
- Perri T, "Effect of treatment delay on survival in patients with cervical cancer : a historical cohort study", Int J Gynecol Cancer, 24, pp.1326~1332 (2014)
- Kulisara Nanthamongkolkul, "Longer waiting times for early stage cervical cancer patients undergoing radical hysterectomy are associated with diminished long-term overall survival", Journal of Gynecologic Oncology, 26(4), pp.262~269 (2015), 대한부인종양학회
- Chen CP, "Effect of time interval from diagnosis to treatment for cervical cancer on survival : a nationwide cohort study", PLoS One, 14, pp.e0221946~ (2019)
- Paik ES, "Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis", Gynecol Oncol, 143, pp.252~257 (2016)
- Capelle L, "Management pathway for patients with cervical cancer in the Auckland region 2003-2007", J Med Imaging Radiat Oncol, 55, pp.337~343 (2011)
- Shen SC, "Factors involved in the delay of treatment initiation for cervical cancer patients : a nationwide population-based study", Medicine(Baltimore), 95, pp.e4568~ (2016)
- Strohl AE, "Surgical wait time : a new health indicator in women with endometrial cancer", Gynecol Oncol, 141, pp.511~515 (2016)
- Elit LM, "Impact of wait times on survival for women with uterine cancer", J Clin Oncol, 32, pp.27~33 (2014)
- Gyenwali D, "Estimates of delays in diagnosis of cervical cancer in Nepal", BMC Womens Health, 14, pp.29~ (2014)
- Allgar VL, "Delays in the diagnosis of six cancers : analysis of data from the National Survey of NHS Patients : cancer", Br J Cancer, 92, pp.1959~1970 (2005)
- Hansen RP, "Socioeconomic patient characteristics predict delay in cancer diagnosis : a Danish cohort study", BMC Health Serv Res, 8, pp.49~ (2008)
- Ma S, "Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: a meta-analysis of randomized controlled trials", Gynecol Oncol, 154, pp.246~252 (2019)